Multiple Myeloma Research Consortium Initiates Phase 1B Study Of Elotuzumab Monoclonal Antibody In Combination With REVLIMID And Dexamethasone

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID^ (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St.